These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29467943)

  • 1. The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction.
    Jomrich G; Hollenstein M; John M; Baierl A; Paireder M; Kristo I; Ilhan-Mutlu A; Asari R; Preusser M; Schoppmann SF
    Oncotarget; 2018 Jan; 9(6):6968-6976. PubMed ID: 29467943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?
    Walsh SM; Casey S; Kennedy R; Ravi N; Reynolds JV
    J Surg Oncol; 2016 Jun; 113(7):732-7. PubMed ID: 27004839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
    Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.
    Hacker UT; Hasenclever D; Baber R; Linder N; Busse H; Obermannova R; Zdrazilova-Dubska L; Valik D; Lordick F
    Ann Oncol; 2022 Jul; 33(7):685-692. PubMed ID: 35395383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-sensitivity modified Glasgow prognostic score (HS-mGPS) Is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy.
    Chen P; Fang M; Wan Q; Zhang X; Song T; Wu S
    Oncotarget; 2017 Nov; 8(59):99861-99870. PubMed ID: 29245945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Treatment Response and Survival with Chemotherapy for Metastatic Penile Cancer by the Modified Glasgow Prognostic Score.
    Draeger DL; Groh S; Buchholz T; Woehl M; Nolting J; Hakenberg OW
    Urol Int; 2023; 107(5):489-495. PubMed ID: 34610603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
    Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
    Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment.
    Ishihara H; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
    Target Oncol; 2016 Oct; 11(5):605-617. PubMed ID: 27023922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer.
    Hanai N; Sawabe M; Kimura T; Suzuki H; Ozawa T; Hirakawa H; Fukuda Y; Hasegawa Y
    Oncotarget; 2018 Dec; 9(97):37008-37016. PubMed ID: 30651931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
    Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
    Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
    Ishizuka M; Nagata H; Takagi K; Kubota K
    Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host.
    Park JH; Watt DG; Roxburgh CS; Horgan PG; McMillan DC
    Ann Surg; 2016 Feb; 263(2):326-36. PubMed ID: 25575264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer.
    Hefler-Frischmuth K; Seebacher V; Polterauer S; Tempfer C; Reinthaller A; Hefler L
    Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):102-5. PubMed ID: 20080329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
    Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
    Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care.
    Pantano Nde P; Paiva BS; Hui D; Paiva CE
    J Pain Symptom Manage; 2016 Feb; 51(2):270-7. PubMed ID: 26598040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction.
    Feka J; Jomrich G; Winkler D; Ilhan-Mutlu A; Kristo I; Paireder M; Rieder E; Bologheanu M; Asari R; Schoppmann SF
    Langenbecks Arch Surg; 2023 Sep; 408(1):351. PubMed ID: 37673810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
    Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
    Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation-based prognostic score predicts biliary stent patency in patients with unresectable malignant biliary obstruction.
    Iwasaki Y; Ishizuka M; Kato M; Kita J; Shimoda M; Kubota K
    Anticancer Res; 2014 Jul; 34(7):3617-22. PubMed ID: 24982377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the Modified Glasgow Prognostic Score (mGPS) as a Prognostic Factor in Metastatic Colorectal Cancer.
    Cotan H; Iaciu C; Nitipir C
    Cureus; 2024 Jul; 16(7):e64916. PubMed ID: 39156325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.